Penny stocks often get written off as pure speculation, yet the Financially Fit Penny Stocks screener aims to spotlight a very different corner of this space. With global markets wrestling with higher for longer rates, sticky energy driven inflation and mixed growth signals, many investors are hunting for lower priced stocks backed by healthier balance sheets. This screener focuses on companies under 5 that also show stronger financial footing than many early stage peers. That combination can appeal if you are looking for calculated risk rather than a punt. In this article you will see three of the best stocks from this screener.
Overview: DroneShield is a Sydney based defence technology company that builds hardware and software systems to detect and counter hostile drones for defence, national security, critical infrastructure, and major event customers around the world.
Operations: DroneShield currently reports all revenue from Aerospace & Defense activities of about A$216.8 million, with A$194.9 million from Australia and the rest of the world and A$29.7 million from the USA.
Market Cap: A$1.65b
DroneShield sits at the intersection of growing counter drone demand and a business model that is shifting toward repeat institutional orders from defence and security agencies. The company has recently turned profitable, with earnings and revenue both forecast to grow much faster than the wider Australian market, helped by contracts such as the A$23.2 million European defence deals and deployments for events like the FIFA World Cup 2026. That growth story is balanced by real risks, including procurement delays, still low return on equity and an ASIC investigation into past announcements and trading activity. For investors, the real question is whether the order book, margins and governance can mature fast enough to justify the current premium pricing.
DroneShield’s rapid shift to repeat defence contracts hints at a bigger story investors may be missing around its future earnings profile. Get the full context in the analyst forecasts for DroneShield and see what might upset the current narrative.
Overview: Sigma Healthcare is a long established Australian company that franchises and supports pharmacy brands such as Chemist Warehouse, Amcal and Discount Drug Stores, supplies medicines wholesale to community pharmacies, and provides logistics and health services across its retail and online channels.
Operations: Sigma Healthcare generates about A$9.5b in revenue, almost entirely from healthcare activities, with A$9.2b from Australia and A$389.8m from international markets.
Market Cap: A$34.28b
Sigma Healthcare offers investors a mix of earnings growth and questions around quality and price. Earnings have grown over five years and are forecast to keep rising, supported by A$9.5b of healthcare revenue in a sector that is often described as resilient. At the same time, profit margins have narrowed, return on equity is in the low teens, and the stock trades on a relatively high P/E multiple compared with both its own estimated fair level and healthcare peers. In addition, the company has higher reliance on external borrowings and a relatively inexperienced board and management team. Overall, this is a business that may warrant close scrutiny rather than blind confidence.
Acceleration at Sigma Healthcare may be more about how quality, debt and pricing interact than headline growth. Walk through the analysis report for Sigma Healthcare to see what could quietly reshape the story next
Overview: Stanmore Resources is a Brisbane based coal producer that explores, develops, mines and sells metallurgical coal used in steelmaking, with a large tenement footprint across Queensland's Bowen and Surat basins and backing from majority owner Golden Investments.
Operations: Stanmore Resources generates about US$1.88b in revenue from producing and selling metallurgical and thermal coal, with most sales going to Asia and the balance to Europe and South America.
Market Cap: A$2.19b
Stanmore Resources attracts investor attention because it combines a sizeable metallurgical coal business with cost efficiency efforts and a dividend yield of about 5.3%. The stock trades below some estimates of fair value. Key risks include volatile coal prices, concentrated Queensland operations that are exposed to weather and regulation, and reliance on steel demand in Asia. A central consideration for investors is whether margins and cash flows will be sufficient to offset those pressures when assessing the company’s valuation.
Stanmore Resources appears to be a valuation story that many investors only partially recognise. The company has a sizeable coal business, a strong cost focus and income appeal, which may be masking one crucial pressure in the analysis report for Stanmore Resources
The three stocks in this article are just a starting point, since the full Financially Fit Penny Stocks screener surfaced 401 more companies with equally compelling financial stories through the Financially Fit Penny Stocks screener. Use Simply Wall St to identify and analyze the exact catalysts, balance sheet strength and earnings narratives that matter to you, so you can focus on the highest conviction ideas in this space.
If Stanmore Resources or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Fresh opportunities can move from quiet to flying quickly. Use these screeners to spot potential breakouts that are under the radar for now, before the crowd catches up, and act now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com